PROLEUKIN
LOE Approachingaldesleukin
BLAINTRAVENOUSVIAL
Approved
May 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROLEUKIN (aldesleukin) is a recombinant interleukin-2 (IL-2) lymphocyte growth factor administered intravenously as a vial formulation. It stimulates T-cell proliferation and activation to enhance immune response against malignant cells. This biologic was approved in 1992 and remains a key immunotherapy agent.
LOE Approaching
LOE-approaching lifecycle stage with moderate competitive pressure (30) suggests a contracting commercial footprint and stable, smaller team size focused on optimization and transition planning.
Mechanism of Action
Pharmacologic Class:
Lymphocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Started Aug 2026
510 enrolled
Moderate-to-Severe Atopic Dermatitis
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Started Jun 2026
510 enrolled
Moderate-to-Severe Atopic Dermatitis
A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.
Started Oct 2025
46 enrolled
Locally Advanced Soft Tissue Sarcoma
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
Started Apr 2024
94 enrolled
Alopecia Areata
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Started Nov 2023
396 enrolled
Moderate to Severe Atopic Dermatitis
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.